Which has higher earnings & valuation, CALC or KALA?

CalciMedica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A KALA BIO N/A N/A -$26.98M -$96.14 N/A

Is CALC or KALA more profitable?

CalciMedica's return on equity of -863.40% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% KALA BIO N/A -1,336.10% -94.85%

Do analysts prefer INCR or CALC?

CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,574.20%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is INCR or CALC more profitable?

InterCure's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets InterCure N/A N/A N/A CalciMedica N/A -863.40% -144.33%

Does the media prefer INCR or CALC?

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 1.00 beat CalciMedica's score of 0.00 indicating that InterCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InterCure 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CalciMedica 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, CALC or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Instil Bio N/A N/A -$71.37M -$7.08 N/A

Is CALC or TIL more profitable?

Instil Bio's return on equity of -39.76% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Instil Bio N/A -39.76% -22.38%

Which has preferable valuation and earnings, PDSB or CALC?

PDS Biotechnology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A CalciMedica N/A N/A -$29.56M -$1.31 N/A

Is PDSB or CALC more profitable?

PDS Biotechnology's return on equity of -346.02% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% CalciMedica N/A -863.40% -144.33%

Is CALC or TLPH more profitable?

Talphera's return on equity of -92.98% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Talphera N/A -92.98% -53.22%

CalciMedica (CALC) Competitors

$0.60 -0.21 (-25.64%)

Closing price 04:00 PM Eastern

Extended Trading

$0.61 +0.01 (+1.96%)

As of 07:58 PM Eastern

Compare

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

Should you buy CalciMedica stock or one of its competitors? MarketBeat compares CalciMedica with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CalciMedica include KALA BIO (KALA), InterCure (INCR), Instil Bio (TIL), PDS Biotechnology (PDSB), and Talphera (TLPH). These companies are all part of the "pharmaceutical products" industry.

How does CalciMedica compare to KALA BIO?

CalciMedica (NASDAQ:CALC) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, media sentiment, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation.

CalciMedica is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

CalciMedica has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, KALA BIO has a beta of -2.4, indicating that its share price is 340% less volatile than the broader market.

In the previous week, CalciMedica had 2 more articles in the media than KALA BIO. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for KALA BIO. CalciMedica's average media sentiment score of 0.00 equaled KALA BIO'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
KALA BIO	Neutral

24.6% of KALA BIO shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by company insiders. Comparatively, 2.2% of KALA BIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

CalciMedica's return on equity of -863.40% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
KALA BIO	N/A	-1,336.10%	-94.85%

CalciMedica currently has a consensus target price of $10.00, indicating a potential upside of 1,574.20%. KALA BIO has a consensus target price of $1,018.75, indicating a potential upside of 33,858.33%. Given KALA BIO's higher probable upside, analysts clearly believe KALA BIO is more favorable than CalciMedica.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

CalciMedica and KALA BIO tied by winning 5 of the 10 factors compared between the two stocks.

How does CalciMedica compare to InterCure?

InterCure (NASDAQ:INCR) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

InterCure has higher revenue and earnings than CalciMedica. CalciMedica is trading at a lower price-to-earnings ratio than InterCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InterCure	$78.47M	0.70	-$10.37M	$0.03	33.33
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,574.20%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

InterCure's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InterCure	N/A	N/A	N/A
CalciMedica	N/A	-863.40%	-144.33%

InterCure has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

8.3% of InterCure shares are held by institutional investors. 0.2% of InterCure shares are held by company insiders. Comparatively, 41.6% of CalciMedica shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, InterCure and InterCure both had 2 articles in the media. InterCure's average media sentiment score of 1.00 beat CalciMedica's score of 0.00 indicating that InterCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InterCure	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CalciMedica	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

InterCure beats CalciMedica on 9 of the 13 factors compared between the two stocks.

How does CalciMedica compare to Instil Bio?

CalciMedica (NASDAQ:CALC) and Instil Bio (NASDAQ:TIL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, dividends, institutional ownership, analyst recommendations, earnings and valuation.

In the previous week, CalciMedica had 2 more articles in the media than Instil Bio. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Instil Bio. CalciMedica's average media sentiment score of 0.00 equaled Instil Bio'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Instil Bio	Neutral

CalciMedica presently has a consensus price target of $10.00, indicating a potential upside of 1,574.20%. Instil Bio has a consensus price target of $66.00, indicating a potential upside of 763.87%. Given CalciMedica's stronger consensus rating and higher possible upside, equities analysts clearly believe CalciMedica is more favorable than Instil Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Instil Bio is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Instil Bio	N/A	N/A	-$71.37M	-$7.08	N/A

Instil Bio's return on equity of -39.76% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Instil Bio	N/A	-39.76%	-22.38%

CalciMedica has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Instil Bio has a beta of 1.91, indicating that its stock price is 91% more volatile than the broader market.

60.6% of Instil Bio shares are held by institutional investors. 41.6% of CalciMedica shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

CalciMedica beats Instil Bio on 7 of the 12 factors compared between the two stocks.

How does CalciMedica compare to PDS Biotechnology?

PDS Biotechnology (NASDAQ:PDSB) and CalciMedica (NASDAQ:CALC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

PDS Biotechnology presently has a consensus price target of $9.00, indicating a potential upside of 929.98%. CalciMedica has a consensus price target of $10.00, indicating a potential upside of 1,574.20%. Given CalciMedica's higher probable upside, analysts plainly believe CalciMedica is more favorable than PDS Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

PDS Biotechnology's return on equity of -346.02% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
CalciMedica	N/A	-863.40%	-144.33%

26.8% of PDS Biotechnology shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 41.6% of CalciMedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, CalciMedica had 2 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 0.00 equaled CalciMedica'saverage media sentiment score.

Company	Overall Sentiment
PDS Biotechnology	Neutral
CalciMedica	Neutral

PDS Biotechnology has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, CalciMedica has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

PDS Biotechnology is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A

Summary

PDS Biotechnology beats CalciMedica on 7 of the 12 factors compared between the two stocks.

How does CalciMedica compare to Talphera?

CalciMedica (NASDAQ:CALC) and Talphera (NASDAQ:TLPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

37.7% of Talphera shares are owned by institutional investors. 41.6% of CalciMedica shares are owned by insiders. Comparatively, 3.5% of Talphera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

CalciMedica presently has a consensus price target of $10.00, suggesting a potential upside of 1,574.20%. Talphera has a consensus price target of $3.00, suggesting a potential upside of 183.02%. Given CalciMedica's higher probable upside, equities research analysts plainly believe CalciMedica is more favorable than Talphera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Talphera	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Talphera's return on equity of -92.98% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Talphera	N/A	-92.98%	-53.22%

CalciMedica has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Talphera has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market.

In the previous week, CalciMedica had 2 more articles in the media than Talphera. MarketBeat recorded 2 mentions for CalciMedica and 0 mentions for Talphera. CalciMedica's average media sentiment score of 0.00 equaled Talphera'saverage media sentiment score.

Company	Overall Sentiment
CalciMedica	Neutral
Talphera	Neutral

Talphera has higher revenue and earnings than CalciMedica. Talphera is trading at a lower price-to-earnings ratio than CalciMedica, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Talphera	$30K	1,833.80	-$14.29M	-$0.31	N/A

Summary

Talphera beats CalciMedica on 8 of the 13 factors compared between the two stocks.

Get CalciMedica News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALC vs. The Competition

Export

Metric	CalciMedica	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.69M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-0.46	20.50	25.39	23.96
Price / Sales	N/A	328.65	530.17	107.90
Price / Cash	N/A	130.96	45.29	53.76
Price / Book	-1.30	8.26	10.76	6.41
Net Income	-$29.56M	$23.91M	$3.56B	$337.14M
7 Day Performance	-28.89%	3.05%	1.37%	-0.48%
1 Month Performance	-5.02%	2.40%	0.81%	0.49%
1 Year Performance	-63.80%	56.35%	30.53%	28.16%

CalciMedica Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALC CalciMedica	1.3741 of 5 stars	$0.60 -25.6%	$10.00 +1,574.2%	-47.8%	$12.69M	N/A	N/A	30	News Coverage High Trading Volume
KALA KALA BIO	1.8286 of 5 stars	$2.85 -9.2%	$1,018.75 +35,645.6%	-98.4%	$52.98M	N/A	N/A	30
INCR InterCure	1.1696 of 5 stars	$0.94 -2.2%	N/A	-28.5%	$51.34M	$78.47M	31.30	350	Gap Down
TIL Instil Bio	1.512 of 5 stars	$7.56 -0.7%	$66.00 +773.0%	-74.7%	$51.27M	N/A	N/A	410
PDSB PDS Biotechnology	2.4958 of 5 stars	$0.91 -5.3%	$9.00 +890.1%	-40.8%	$50.74M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALC) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CalciMedica (CALC) Competitors

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

How does CalciMedica compare to KALA BIO?

Summary

How does CalciMedica compare to InterCure?

Summary

How does CalciMedica compare to Instil Bio?

Summary

How does CalciMedica compare to PDS Biotechnology?

Summary

How does CalciMedica compare to Talphera?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CalciMedica (CALC) Competitors

CALC vs. KALA, INCR, TIL, PDSB, and TLPH

How does CalciMedica compare to KALA BIO?

Which has higher earnings & valuation, CALC or KALA?

Which has more volatility & risk, CALC or KALA?

Does the media refer more to CALC or KALA?

Do insiders & institutionals hold more shares of CALC or KALA?

Is CALC or KALA more profitable?

Do analysts rate CALC or KALA?

Summary

How does CalciMedica compare to InterCure?

Which has higher earnings and valuation, INCR or CALC?

Do analysts prefer INCR or CALC?

Is INCR or CALC more profitable?

Which has more volatility and risk, INCR or CALC?

Do insiders & institutionals believe in INCR or CALC?

Does the media prefer INCR or CALC?

Summary

How does CalciMedica compare to Instil Bio?

Does the media favor CALC or TIL?

Do analysts rate CALC or TIL?

Which has preferable valuation and earnings, CALC or TIL?

Is CALC or TIL more profitable?

Which has more risk & volatility, CALC or TIL?

Do insiders and institutionals believe in CALC or TIL?

Summary

How does CalciMedica compare to PDS Biotechnology?

Do analysts rate PDSB or CALC?

Is PDSB or CALC more profitable?

Do institutionals and insiders believe in PDSB or CALC?

Does the media refer more to PDSB or CALC?

Which has more risk and volatility, PDSB or CALC?

Which has preferable valuation and earnings, PDSB or CALC?

Summary

How does CalciMedica compare to Talphera?

Do institutionals & insiders have more ownership in CALC or TLPH?

Do analysts prefer CALC or TLPH?

Is CALC or TLPH more profitable?

Which has more volatility and risk, CALC or TLPH?

Does the media favor CALC or TLPH?

Which has preferable valuation and earnings, CALC or TLPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALC vs. The Competition

CalciMedica Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools